# Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

> **NCT03065790** · — · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 1 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DIAGNOSTIC_TEST:** 2-Deoxy-2-[18F]fluoro-D-glucose (FDG)

## Key facts

- **NCT ID:** NCT03065790
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-06
- **Primary completion:** 2021-04-28
- **Final completion:** 2021-04-28
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Adequate recruitment was not reached to continue the study.
- **Last updated:** 2021-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03065790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03065790, "Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03065790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*